Cidara Therapeutics Inc.
Cidara Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Updates
Summary
Cidara Therapeutics, Inc. reported financial results for the second quarter ended June 30, 2024. The company reported a net loss of $91.2 million for the quarter compared to a net loss of $13.6 million in the same period last year. Key highlights include the reacquisition of exclusive global development and commercial rights to CD388, a $240.0 million private placement, and the divestiture of rezafungin to Mundipharma. Cidara also received IND clearance for CBO421. The company's cash and cash equivalents totaled $164.4 million as of June 30, 2024.
Profitelligence Alerts
Get alerts for CDTX
Be first to know when Cidara Therapeutics Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Cidara Therapeutics Inc.
Cidara Therapeutics Inc. is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives and immunotherapies. Its primary function involves addressing unmet medical needs in the treatment of serious infectious diseases and immune-based conditions. Emphasizing innovation, Cidara Therapeutics is known for its pioneering Cloudbreak platform, which integrates potent drug conjugates designed to address life-threatening bacterial, viral, and fungal infections. The asset prominently impacts the biotechnology and pharmaceutical sectors, endeavoring to transform standard infection treatments with its advanced therapeutic solutions. Cidara's pipeline includes the development of new antifungal agents like rezafungin, aimed at treating invasive fungal infections that significantly affect immunocompromised patients. With its strategic focus, Cidara Therapeutics plays a critical role in the emerging markets of antimicrobial resistance and immunotherapy. Positioned within the healthcare industry, Cidara's contributions hold significant potential to alter existing therapies and specialize in meeting complex medical challenges, reinforcing the broader landscape of pharmaceutical advancements and patient care strategies.
Official SEC Documents
Advertisement